EVERYTHING ABOUT TYROSINASE-IN-12

MI-CP151 was a section 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study to evaluate numerous intravenous doses of sifalimumab, in adult sufferers with dermatomyositis or polymyositis (NCT00533091). Most important demo aims ended up To judge the security and tolerability of sifalimumab in dermatomyositis or polymyosit